Galectin Therapeutics Inc. (GALT)
Nasdaq · Healthcare · Biotechnology
$3.73−4.36%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $376M
- 52-week range
- $2.03 – $7.13
- 52-week change
- −12.16%
- EPS (trailing)
- −$0.41
Fiscal year to Dec 2025
- Net income
- −$30.8M
- Diluted EPS
- −$0.48
From the company’s annual report on SEC EDGAR.
About Galectin Therapeutics Inc.
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc. to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Headquarters: Norcross, United States · 9 employees · galectintherapeutics.com